Protagonist Therapeutics (PTGX) Assets Average (2016 - 2026)

Protagonist Therapeutics (PTGX) has 11 years of Assets Average data on file, last reported at $682.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 8.15% year-over-year to $682.8 million; the trailing twelve-month figure through Mar 2026 stood at $682.8 million (down 8.15% YoY), and the FY2025 full-year result was $706.5 million, up 28.13% from the prior year.
• Assets Average steadied at $682.8 million in Q1 2026, from $684.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $743.4 million in Q1 2025 to a low of $243.9 million in Q1 2023.
• A 5-year average of $493.1 million and a median of $493.6 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average dropped 29.91% in 2023 and soared 122.0% in 2024, its largest moves.
• Tracing PTGX's Assets Average over 5 years: stood at $265.1 million in 2022, then climbed by 29.78% to $344.0 million in 2023, then surged by 96.02% to $674.3 million in 2024, then grew by 1.58% to $684.9 million in 2025, then slipped by 0.31% to $682.8 million in 2026.
• Business Quant data shows PTGX's Assets Average at $682.8 million in Q1 2026, $684.9 million in Q4 2025, and $709.8 million in Q3 2025.